Common Interest Doctrine and Attorney-Client Privilege Protect Distributor’s Email Communication with Defendant

Feb 3, 2020

Reading Time : 1 min

Plaintiff, Beijing Choice Electronic Technology Co., Ltd. (“Choice”) sued Contec Medical Systems USA, Inc. and Contec Medical Systems Co., Ltd. (collectively, “Contec”) for infringing Choice’s patents related to fingertip pulse oximeters. After the complaint had been filed, an attorney for Choice sent cease-and-desist letters to six Contec distributors, including Veridian Healthcare LLC (“Veridian”). Veridian, in turn, sought advice via email from Contec regarding how best to respond to the cease-and-desist letter. Choice subpoenaed Veridian documents, including its emails and later moved to compel production after Veridian withheld the material on the basis of attorney-client privilege.

The court held that privilege attached to a single email—a filtered summary of an attorney’s opinions regarding the litigation that was primarily legal in nature. The court also found the document implicated the common interest doctrine. Veridian purchased oximeters from Contec that were at the center of the litigation, and after receiving the cease-and-desist letter, Veridian reasonably understood it might face its own lawsuit for selling the allegedly infringing products. The document thus concerned coordination between Veridian and Contec, both of which had an actual legal interest in avoiding liability. Because the privileged status of communications falling within the common interest doctrine cannot be waived without the consent of all parties, the court found the document properly withheld as privileged.

The court held that the remaining documents were not protected by the attorney-client privilege or work product immunity. The court determined the documents did not reveal the substance of any client confidence or opinions of Contec’s counsel. Instead, the documents involved business discussions. As such, the court ordered Veridian to produce them.

Beijing Choice Elec. Tech. Co. v. Contec Med. Sys. USA, Inc., No. 1:18-CV-825, D.I. 182 (N.D. Ill. Jan. 14, 2020)

Share This Insight

Previous Entries

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

IP Newsflash

April 9, 2026

In the April 1, 2026 edition of the Official Gazette, the U.S. Patent and Trademark Office announced a new procedural framework that permits patent owners to submit a limited, early response to a request for ex parte reexamination.

...

Read More

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.